Bristol-Myers Squibb brings Chinese activities under one roof:
This article was originally published in Clinica
Bristol-Myers Squibb will set up a new business unit incorporating all its divisions active in China. The unit will be headed by Jack Wolinetz in the newly-created position of president, China, Bristol-Myers Squibb. He will report to Samuel Hamad, president, intercontinental, who says that BMS has seen significant growth in China as a result of strong relationships with its joint-venture partners and a solid investment strategy. In July, BMS' ConvaTec medical device subsidiary opened its first manufacturing plant in what was BMS' third Chinese joint venture (see Clinica No 661, p 12).